Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance Strategies in ANCA Vasculitis
NCT02749292Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2016
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Massachusetts General Hospital. Started Jun 2016; status: terminated.
02
Drugs
rituximab
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT02749292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749292.